Neurogene Inc. (NGNE)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Neurogene trailed consensus on EPS in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026, with EPS of -$1.53 trailing the -$1.42 estimate by -$0.11 and down from -$1.05 a year ago (-45.7% YoY). The clinical-stage gene therapy developer posted a GAAP net loss of roughly $34.5 million, versus a net loss of about $22.0 million a year ago (-56.6% YoY), alongside an operating loss of around $36.7 million as it continued advancing its pipeline programs, including NGN-401 and NGN-101. Cash burn remained evident, with operating cash flow of about -$23.8 million for the quarter. For the next period, consensus calls for EPS of -$1.39.
About Neurogene Inc.
Neurogene Inc. is a NASDAQ-listed Biotechnology company in healthcare that develops genetic medicines for neurological conditions. The company remains a clinical-stage business rather than a commercial drug seller, and its work centers on rare neurologic disorders through a focused pipeline built around gene therapy candidates.
Today's Snapshot
So far today, NGNE is trading 1.6% lower at 37.28, while its sector was flat.
Trading Volume
Below 10d avg (172.2K)
50.6K
vs S&P 500 Today
Underperforming Market
-1.02%
Updated: September 10, 2026 at 16:59 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.82 - $37.81Buy
- RSI (14)50.45Neutral
- Stochastic %K (14, 3, 3)37.28Neutral
- MACD Level (12, 26)0.52Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.